Abstract
Metabolic syndrome (MetS) is associated with increased risk of both atherothrombotic cardiovascular events and venous thromboembolism. The pro-thrombotic potential of MetS, may explain this association. In this review we discuss the relationship of MetS with hemostasis focusing on endothelial function, platelet activity, coagulation, fibrinolysis and hemorheologic markers. Endothelial-dependent vasodilatation is impaired in MetS. This is mostly mediated by a reduced expression of vasodilators (nitric oxide and prostacyclin) with a concomitant increase of vasoconstrictors (endothelin- 1, angiotensin II and thromboxane A2). Platelet activity is enhanced in MetS. A cross-talk between activated endothelium and platelets results in a pro-thrombotic vicious cycle. Enhanced coagulation together with impaired fibrinolysis is also present in MetS. This is mirrored by high fibrinogen and plasminogen activator inhibitor-1 levels. Endothelial dysfunction, expressed by high von Willebrand factor and tissue plasminogen factor levels, also contributes to this abnormality. Whole blood and plasma viscosity is increased in MetS.
Lifestyle intervention can improve the MetS-related pro-thrombotic state. These measures include weight reduction and improved composition of the diet. A Mediterranean-style diet rich in olive oil, as a source of monounsaturated fat, and low saturated fat consumption may also be beneficial.
Keywords: Metabolic syndrome, hemostasis, endothelium, platelet, coagulation, fibrinolysis, viscosity.
Current Vascular Pharmacology
Title:Hemostatic Factors and the Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Michael S. Kostapanos, Matilda Florentin, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Metabolic syndrome, hemostasis, endothelium, platelet, coagulation, fibrinolysis, viscosity.
Abstract: Metabolic syndrome (MetS) is associated with increased risk of both atherothrombotic cardiovascular events and venous thromboembolism. The pro-thrombotic potential of MetS, may explain this association. In this review we discuss the relationship of MetS with hemostasis focusing on endothelial function, platelet activity, coagulation, fibrinolysis and hemorheologic markers. Endothelial-dependent vasodilatation is impaired in MetS. This is mostly mediated by a reduced expression of vasodilators (nitric oxide and prostacyclin) with a concomitant increase of vasoconstrictors (endothelin- 1, angiotensin II and thromboxane A2). Platelet activity is enhanced in MetS. A cross-talk between activated endothelium and platelets results in a pro-thrombotic vicious cycle. Enhanced coagulation together with impaired fibrinolysis is also present in MetS. This is mirrored by high fibrinogen and plasminogen activator inhibitor-1 levels. Endothelial dysfunction, expressed by high von Willebrand factor and tissue plasminogen factor levels, also contributes to this abnormality. Whole blood and plasma viscosity is increased in MetS.
Lifestyle intervention can improve the MetS-related pro-thrombotic state. These measures include weight reduction and improved composition of the diet. A Mediterranean-style diet rich in olive oil, as a source of monounsaturated fat, and low saturated fat consumption may also be beneficial.
Export Options
About this article
Cite this article as:
Kostapanos S. Michael, Florentin Matilda, Elisaf S. Moses and Mikhailidis P. Dimitri, Hemostatic Factors and the Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113116660171
DOI https://dx.doi.org/10.2174/15701611113116660171 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial
Reviews on Recent Clinical Trials Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research 1h Post-load Blood Glucose in the Identification of Proatherogenic Cardiometabolic Profile in Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets The MAPK / JNK Signalling Pathway Offers Potential Therapeutic Targets for the Prevention of Acquired Deafness
Current Drug Targets - CNS & Neurological Disorders Meet Our Editorial Board Member
Medicinal Chemistry Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Atheroprotective Effects of HDL: Beyond Reverse Cholesterol Transport
Current Drug Targets Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Colesevelam: A New and Improved Bile Acid Sequestrant?
Current Pharmaceutical Design Recent Strategies Combining Biomaterials and Stem Cells for Bone, Liver and Skin Regeneration
Current Stem Cell Research & Therapy Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Cardiovascular Disease in the Systemic Vasculitides
Current Vascular Pharmacology Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Interactions of Polyphenols with Plasma Proteins: Insights from Analytical Techniques
Current Drug Metabolism Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Quantification and Pharmacokinetics Study of Pedunculoside in Rats by Using UPLC-MS/MS
Current Pharmaceutical Analysis Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets